Core Laboratories N.V. (CLB) Financial Ratios
30 years of historical data (1996–2025) · Energy · Oil & Gas Equipment & Services
EV/EBITDA
↓
12.11
↓-27% vs avg
5yr avg: 16.50
30Y Low7.2·High48.7
P/FCF
↓
25.93
↓-41% vs avg
5yr avg: 44.14
30Y Low11.6·High74.9
P/B Ratio
↓
2.11
↓-50% vs avg
5yr avg: 4.20
30Y Low1.5·High53.5
ROE
↓
11.8%
-16% vs avg
5yr avg: 14.0%
30Y Low-76%·High280%
Debt/EBITDA
↓
3.25
↓-1% vs avg
5yr avg: 3.29
30Y Low0.6·High3.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CLB Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Core Laboratories N.V. trades at 18.7x earnings, 46% below its 5-year average of 34.8x, sitting at the 7th percentile of its historical range. Compared to the Energy sector median P/E of 16.4x, the stock trades at a premium of 14%. On a free-cash-flow basis, the stock trades at 25.9x P/FCF, 41% below the 5-year average of 44.1x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $586M | $745M | $825M | $839M | $949M | $1.0B | $1.2B | $1.7B | $2.7B | $4.8B | $5.3B |
| Enterprise Value | $769M | $929M | $986M | $1.0B | $1.2B | $1.3B | $1.5B | $2.1B | $2.9B | $5.1B | $5.5B |
| P/E Ratio → | 18.71 | 23.57 | 26.23 | 22.94 | 48.26 | 53.12 | — | 17.94 | 33.33 | 58.27 | 82.79 |
| P/S Ratio | 1.11 | 1.42 | 1.58 | 1.65 | 1.94 | 2.22 | 2.45 | 2.52 | 3.79 | 7.35 | 8.91 |
| P/B Ratio | 2.11 | 2.66 | 3.20 | 3.65 | 5.02 | 6.47 | 15.78 | 9.23 | 16.08 | 31.77 | 33.28 |
| P/FCF | 25.93 | 33.00 | 19.04 | 59.06 | 64.38 | 45.21 | 25.93 | 25.01 | 29.45 | 45.96 | 44.10 |
| P/OCF | 15.76 | 20.05 | 14.64 | 33.86 | 38.02 | 28.48 | 20.60 | 18.79 | 23.73 | 39.02 | 40.19 |
P/E links to full P/E history page with 30-year chart
CLB EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Core Laboratories N.V.'s enterprise value stands at 12.1x EBITDA, 27% below its 5-year average of 16.5x. The Energy sector median is 8.0x, placing the stock at a 52% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.76 | 1.88 | 2.04 | 2.36 | 2.71 | 3.09 | 3.07 | 4.18 | 7.67 | 9.25 |
| EV / EBITDA | 12.11 | 14.63 | 13.42 | 14.76 | 19.70 | 19.98 | — | 17.21 | 20.68 | 36.96 | 48.67 |
| EV / EBIT | 15.75 | 19.01 | 16.85 | 19.02 | 27.84 | 28.15 | 30.33 | 20.12 | 24.70 | 46.03 | 62.91 |
| EV / FCF | — | 41.12 | 22.75 | 73.15 | 78.42 | 55.30 | 32.74 | 30.52 | 32.52 | 47.98 | 45.78 |
CLB Profitability
Margins and return-on-capital ratios measuring operating efficiency
Core Laboratories N.V. earns an operating margin of 9.3%, below the Energy sector average of 13.8%. Operating margins have compressed from 10.7% to 9.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. ROE of 11.8% is modest. ROIC of 8.3% represents adequate returns on invested capital versus a sector median of 6.2%.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 17.9% | 17.9% | 16.9% | 18.4% | 16.1% | 17.8% | 21.0% | 25.8% | 25.8% | 24.3% | 21.1% |
| Operating Margin | 9.3% | 9.3% | 11.2% | 10.7% | 8.5% | 9.6% | -15.8% | 14.5% | 16.9% | 17.0% | 14.5% |
| Net Profit Margin | 6.0% | 6.0% | 6.0% | 7.2% | 4.0% | 4.2% | -20.0% | 15.3% | 11.3% | 12.6% | 10.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 11.8% | 11.8% | 12.9% | 17.5% | 11.1% | 16.7% | -75.8% | 58.7% | 50.1% | 53.3% | 90.7% |
| ROA | 5.4% | 5.4% | 5.3% | 6.3% | 3.4% | 3.4% | -14.5% | 14.3% | 12.9% | 14.4% | 10.7% |
| ROIC | 8.3% | 8.3% | 10.3% | 9.9% | 7.9% | 8.7% | -12.2% | 14.6% | 22.1% | 23.2% | 17.2% |
| ROCE | 9.9% | 9.9% | 11.8% | 11.2% | 8.6% | 9.3% | -13.5% | 16.0% | 23.1% | 23.7% | 17.7% |
CLB Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Core Laboratories N.V. carries a Debt/EBITDA ratio of 3.2x, which is moderately leveraged (25% above the sector average of 2.6x). Net debt stands at $183M ($206M total debt minus $23M cash). Interest coverage of 5.0x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.74 | 0.74 | 0.70 | 0.94 | 1.18 | 1.55 | 4.33 | 2.10 | 1.76 | 1.49 | 1.36 |
| Debt / EBITDA | 3.25 | 3.25 | 2.45 | 3.06 | 3.79 | 3.92 | — | 3.20 | 2.04 | 1.66 | 1.91 |
| Net Debt / Equity | — | 0.66 | 0.62 | 0.87 | 1.10 | 1.44 | 4.14 | 2.04 | 1.68 | 1.39 | 1.27 |
| Net Debt / EBITDA | 2.89 | 2.89 | 2.19 | 2.84 | 3.53 | 3.65 | — | 3.11 | 1.95 | 1.55 | 1.78 |
| Debt / FCF | — | 8.12 | 3.71 | 14.09 | 14.04 | 10.09 | 6.81 | 5.51 | 3.07 | 2.02 | 1.68 |
| Interest Coverage | 4.95 | 4.95 | 4.73 | 4.07 | 3.59 | 4.95 | 3.45 | 6.94 | 8.90 | 10.24 | 7.56 |
CLB Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Core Laboratories N.V.'s current ratio of 2.07x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.57x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 2.53x to 2.07x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.07 | 2.07 | 2.32 | 2.53 | 2.05 | 2.08 | 1.85 | 1.98 | 2.25 | 1.98 | 1.79 |
| Quick Ratio | 1.57 | 1.57 | 1.71 | 1.72 | 1.47 | 1.58 | 1.42 | 1.53 | 1.81 | 1.66 | 1.47 |
| Cash Ratio | 0.21 | 0.21 | 0.20 | 0.17 | 0.15 | 0.20 | 0.15 | 0.10 | 0.13 | 0.14 | 0.14 |
| Asset Turnover | — | 0.88 | 0.89 | 0.87 | 0.85 | 0.81 | 0.86 | 0.86 | 1.08 | 1.13 | 1.04 |
| Inventory Turnover | 7.93 | 7.93 | 7.33 | 5.80 | 6.80 | 8.50 | 10.10 | 9.88 | 11.39 | 14.98 | 13.92 |
| Days Sales Outstanding | — | 78.70 | 88.74 | 88.11 | 85.79 | 82.85 | 62.32 | 75.44 | 67.26 | 73.63 | 70.17 |
CLB Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Core Laboratories N.V. returns 2.4% to shareholders annually — split between a 0.3% dividend yield and 2.1% buyback yield. The payout ratio of 5.9% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 5.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.3% | 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 1.0% | 5.8% | 3.7% | 2.0% | 1.8% |
| Payout Ratio | 5.9% | 5.9% | 6.0% | 5.1% | 9.5% | 9.3% | — | 95.7% | 122.3% | 116.9% | 148.9% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 5.3% | 4.2% | 3.8% | 4.4% | 2.1% | 1.9% | — | 5.6% | 3.0% | 1.7% | 1.2% |
| FCF Yield | 3.9% | 3.0% | 5.3% | 1.7% | 1.6% | 2.2% | 3.9% | 4.0% | 3.4% | 2.2% | 2.3% |
| Buyback Yield | 2.1% | 1.7% | 0.6% | 0.3% | 0.4% | 0.8% | 0.2% | 0.2% | 0.3% | 0.3% | 0.1% |
| Total Shareholder Yield | 2.4% | 1.9% | 0.9% | 0.5% | 0.6% | 1.0% | 1.3% | 6.0% | 3.9% | 2.4% | 1.9% |
| Shares Outstanding | — | $47M | $48M | $48M | $47M | $47M | $45M | $45M | $44M | $44M | $44M |
Peer Comparison
Compare CLB with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CLBYou | $586M | 18.7 | 12.1 | 25.9 | 17.9% | 9.3% | 11.8% | 8.3% | 3.2 |
 LBRT | $5B | 31.5 | 9.3 | 322.5 | 11.4% | 2.0% | 7.3% | 2.3% | 1.5 |
 NINE | $442M | -8.2 | 16.1 | — | 10.7% | 0.1% | — | 0.1% | 7.7 |
 PUMP | $2B | 1947.4 | 10.4 | 43.8 | 9.9% | 1.5% | 0.1% | 1.4% | 1.3 |
 PTEN | $4B | -44.4 | 5.4 | 10.9 | 4.8% | -0.5% | -2.8% | -0.4% | 1.4 |
 RES | $2B | 45.9 | 6.5 | 28.9 | 14.3% | 3.5% | 2.9% | 4.8% | 0.4 |
 WTTR | $2B | 92.4 | 11.6 | — | 14.0% | 2.5% | 2.3% | 2.3% | 1.8 |
 SLB | $81B | 22.9 | 12.2 | 16.8 | 18.2% | 15.3% | 13.5% | 12.1% | 1.7 |
 HAL | $32B | 25.5 | 11.1 | 19.1 | 15.7% | 10.2% | 12.2% | 10.2% | 2.4 |
 BKR | $62B | 24.0 | 13.8 | 24.4 | 23.6% | 12.8% | 14.4% | 12.7% | 1.5 |
 NCSM | $141M | 6.2 | 6.6 | 6.7 | 38.2% | 6.4% | 18.3% | 7.9% | 0.7 |
| Energy Median | — | 16.4 | 8.0 | 14.3 | 33.7% | 13.8% | 7.2% | 6.2% | 2.6 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
What if you invested $1,000 in CLB 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in CLB be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs CLB Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCLB vs LBRT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Liberty Energy Inc..
Compare NowCLB — Frequently Asked Questions
Quick answers to the most common questions about buying CLB stock.
What is Core Laboratories N.V.'s P/E ratio?
Core Laboratories N.V.'s current P/E ratio is 18.7x. The historical average is 33.7x. This places it at the 7th percentile of its historical range.
What is Core Laboratories N.V.'s EV/EBITDA?
Core Laboratories N.V.'s current EV/EBITDA is 12.1x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 17.6x.
What is Core Laboratories N.V.'s ROE?
Core Laboratories N.V.'s return on equity (ROE) is 11.8%. The historical average is 53.2%.
Is CLB stock overvalued?
Based on historical data, Core Laboratories N.V. is trading at a P/E of 18.7x. This is at the 7th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Core Laboratories N.V.'s dividend yield?
Core Laboratories N.V.'s current dividend yield is 0.32% with a payout ratio of 5.9%.
What are Core Laboratories N.V.'s profit margins?
Core Laboratories N.V. has 17.9% gross margin and 9.3% operating margin.
How much debt does Core Laboratories N.V. have?
Core Laboratories N.V.'s Debt/EBITDA ratio is 3.2x, indicating high leverage. A ratio between 2-4x is manageable but warrants monitoring.